Utility of testing for third-generation anticyclic citrullinated peptide (anti-CCP3) antibodies in individuals who present with new musculoskeletal symptoms but have a negative second-generation anticyclic citrullinated peptide (anti-CCP2) antibody test.
Andrea Di MatteoKulveer MankiaLeticia Garcia-MontoyaSana SharrackLaurence DuquenneJacqueline L NamMichael MahlerPaul EmeryPublished in: RMD open (2024)
Anti-CCP3 testing could improve the prediction of IA development in anti-CCP2- individuals with new MSK symptoms.
Keyphrases